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Abstract 
An immunoglobulin light chain (L chain) library derived from the peripheral blood lymphocytes of a patient with asthma was cloned 
into a phagemid vector. Phage particles displaying L chains capable of binding vasoactive intestinal polypeptide (VIP) were isolated by 
affinity chromatography. Two VIP binding L chains were expressed in Escherichia coli in soluble form and purified to electrophoretic 
homogeneity by metal chelating and protein L affinity chromatography. Both L chains catalyzed the hydrolysis of [tyr m tzSI]VIP 
substrate. The catalytic activity eluted at the molecular mass of the monomer form of the L chain (28 kDa) from a gel filtration column. 
The activity was bound by immobilized anti-K-chain antibody. A control recombinant L chain displayed no catalytic activity. Hydrolysis 
of VIP by the catalytic L chains was saturable and consistent with Michaelis-Menten kinetics. The turnover of the L chains was moderate 
(0.22 and 2.21/min) and their K m values indicated comparatively high affinity recognition of VIP [111 and 202 riM), producing catalytic 
efficiencies comparable toor greater than trypsin. Unlike trypsin, the L chains did not display detectable cleavage of casein, suggesting a 
catalytic activity specialized for V1P. Comparisons of the nucleotide sequences of the L chain cDNA with their putative germ-line 
counterparts suggested the presence of several replacement mutations in the complementarity determining regions (CDRs). These 
observations suggest: (a) Retention or acquisition of catalytic activity by the L chains is compatible with affinity maturation of antibodies: 
and (b) The autoimmune L chain repertoire can serve as a source of substrate-specific and efficient catalysts. 
Kevwords: Catalytic antibody: Autoantibody; Light chain; Vasoactive intestinal polypeptide; Asthma; Phage display 
1. Introduction 
Catalysis occurs by stabilization of substrate transition 
states. It has been commonly assumed, therefore, that 
immunization with structural analogs of the transition state 
is necessary to induce catalytic antibody formation (re- 
viewed in Ref. [1]). Contrary to this assumption, poly- 
clonal human autoantibodies are demonstrated to catalyze 
energetically demanding reactions like peptide and DNA 
hydrolysis with kinetic efficiencies comparable to those of 
enzymes [2-7]. Furthermore, mouse strains genetically 
predisposed to autoimmune disease appear to mount sub- 
stantially stronger catalytic antibody responses to a transi- 
tion state analog than control animals [8], supporting the 
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association of catalytic activity with autoimmune reactivity 
deduced from human studies. The life-times of substrate 
transition states are exceedingly short, being of the order 
of bond vibration and rotation frequencies. Sensitization of 
the immune system by transition states, therefore, is an 
unlikely mechanism for the formation of catalytic autoanti- 
bodies. More plausible explanations for the phenomenon 
of autoantibody catalysis are: (a) the catalytic activity may 
be encoded by a germ-line variable region (V-region) 
gene(s) or developed e novo over the course of affinity 
maturation of this gene, and (b) Anti-idiotypic antibodies 
to anti-enzyme autoantibodies found in autoimmune dis- 
ease may display catalytic activity by mimicking the struc- 
tural features of the enzyme active site. These possibilities 
are based on observations of catalysis by antibodies and 
antibody light chains (L chains) elicited by immunization 
with the ground state of ordinary antigens [9-11], presence 
of polyreactive catalytic antibodies in unimmunized onors 
[12], apparently fortuitous hydrolysis of a substrate unre- 
lated in structure to the immunogen [13] and examples of 
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catalysis by anti-idiotypic antibodies to anti-acetylcholin- 
esterase [14] and anti-DNase antibodies [15]. 
Vasoactive intestinal polypeptide (VIP) is a neuropep- 
tide with potent smooth muscle relaxant, anti-inflammatory 
and tumor growth promoting effects [16-18]. Polyclonal 
autoantibodies and their L chain subunits capable of cat- 
alyzing the cleavage of VIP have been identified in pa- 
tients with respiratory disorders [2,3,19,20] and classical 
autoimmune diseases like systemic lupus erythematosus 
(S. Paul and coworkers, unpublished results). The aim of 
the present study was to clone human autoantibody L 
chains capable of catalyzing the hydrolysis of VIP. This 
aim is driven by the need for homogeneous human anti- 
body preparations suitable for study of the possible patho- 
genetic role of VIP antibodies in autoimmune disease, as 
well the potential utility of the catalytic antibodies as 
anti-tumor agents. By using phage display methods, two L 
chains with VIP cleaving activity have been cloned. The 
catalytic efficiency of the L chains is comparable totrypsin. 
Unlike trypsin, the L chains are selective for VIP. 
subjected to affinity chromatography on a VIP-Sepharose 
column [22]. Two clones isolated from the pH 5.5 eluate of 
this column (designated clones hkl 3 and bkl4) were shown 
to bind VIP by radioimmunoassay and ELISA [24]. These 
were grown in E. coli HB2151 cells and the cultures were 
induced with IPTG (1 mM) for 24 h to permit secretion of 
soluble L chains into the supernatant. The expression level 
of the recombinant L chains in the culture supernatants 
was ~ 0.5 rag/liter, estimated by enzyme-linked im- 
munoflow assay for c-myc stainable protein [22]. For 
expression of L chains in the periplasm, induction of the 
cultures with IPTG was for 3 h. Periplasmic extract prepa- 
ration was as in [25]. A control catalytic L chain and a 
non-catalytic L chain from murine hybridoma cell-lines 
c23.5 and c23.1 [9], respectively, were cloned in 
pCANTAB5his  6 vector [25], except hat the 5' back primer 
used for c23.1 L chain amplification was GTCCTCG- 
CAACTGC GGCCCAGCCGGCCATGGCC(A/C)A(C /  
T)A TTGT(A/G/T)CT(G/C)ACCCAGTCTCC (SfiI re- 
striction site is underlined). 
2. Materials and methods 2.3. Purification of  L chains 
2.1. Reagents 
Phagemid vector pCANTAB5his  6 and Escherichia coli 
strains TGI and HB2151 were from Cambridge Antibody 
Technologies, Cambridgeshire, UK. Protein L was kindly 
provided by Dr. L. BjiSrk, University of Lund, Sweden 
[21]. Synthetic VIP was purchased from Bachem, Tor- 
rance, California. Polymerase chain reation (PCR) primers 
were synthesized and HPLC-purified by National Bio- 
sciences, Plymouth, MN. VCSM13 helper phage was from 
Stratagene, La Jolla, CA. Hybridoma cell line 9El0 pro- 
ducing anti-c-myc antibody was from American Type Cul- 
ture Collection (Rockville, MD), polyethylene glycol (M r 
8000) from Sigma (St. Louis, MO), isopropyl-[3-D-thio- 
galactopyranoside (IPTG) from Clontech (Palo Alto, CA) 
and resorufin-casein from Boehringer-Mannheim (Indi- 
anapolis, IN). 
2.2. Recombinant L chains 
L chain cDNA was prepared from the peripheral blood 
lymphocytes of a patient with exercise-induced asthma by 
the reverse transcriptase-PCR method. KBACKI primer, 
KFOR primer and PCR conditions used for cDNA amplifi- 
cation are described in [22]. The PCR products were 
cloned into the phagemid vector pCANTAB5his  6, which 
allows display of L chains on the surface of phage parti- 
cles or their expression as soluble proteins [23]. Following 
electroporation f competent E. coli TGI cells with the 
phagemid DNA, phage particles displaying L chains fused 
to protein 3 were rescued by superinfection with VCSM13 
helper phage, precipitated with polyethylene glycol and 
The cloned L chains contain a C-terminal hexahistidine 
tag, permitting their purification by immobilized metal 
affinity chromatography (IMAC). The bacterial culture 
supernatant (l liter) was concentrated 5-fold using a Pelli- 
con tangential flow ultrafiltration system (Millipore, 10 
kDa PGLC filter) and dialyzed overnight at 4°C against 10 
liters of buffer A (50 mM Tris-HCl, pH 7.2, 0.5 M NaCI, 
0.025% Tween-20, 10% glycerol, 5 mM 13-mercapto- 
ethanol, 0.02% sodium azide). The recombinant protein 
was allowed to bind Ni-NTA gel (25 ml; Qiagen, 
Chatsworth, IL) in buffer A with end-to-end mixing (1 h, 
4°C), the gel was packed into a column and washed with 
buffer A (4 ml/min) until a stable baseline (A280) was 
reached. Bound protein was eluted (2 ml/min) with a 
gradient of 0-100% buffer B (50 mM Tris-HC1, pH 7.2, 
0.5 M NaCI, 1 M imidazole, 0.02% sodium azide; 50 min) 
followed by 100% buffer B (10 min). Elution of the L 
chain in the fractions (1 min each) was monitored by 
enzyme-linked immunoflow assay for c-myc [22]. Chro- 
matography on protein L coupled to CNBr-activated 
Sepharose 4B was as described [26]. Size exclusion chro- 
matography was on a Superose-12 high performance gel 
filtration column (Pharmacia) in 50 mM Tris-HC1, pH 7.2, 
0.5 M NaCI, 0.025% Tween-20 (0.4 ml/min). The column 
fractions (0.4 ml) were dialyzed overnight against 50 mM 
Tris-HCl, pH 8.0, 0.1 M glycine, 0.025% Tween-20 using 
a Life Technologies multi-well apparatus and assayed for 
[tyrm-125I]VIP hydrolyzing activity. In a preliminary 
screening experiment, the two human L chains (designated 
hkl3 and hkl4), a murine catalytic L chain (clone c23.5) 
and a murine non-catalytic L chain (clone c23.1) were 
purified from periplasmic extracts (7 ml prepared from 250 
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ml of the bacterial culture) on 1 ml Ni-NTA gel packed in 
a disposable polypropylene column (Qiagen, Chatsworth, 
IL) [27]. Bound L chains were eluted with 9 ml imidazole 
buffer (buffer B) and the eluate was assayed for the ability 
to hydrolyze [tyr~°-125I]VIP. rotein purity was assessed 
by SDS-polyacrylamide g l electrophoresis (8-25% gradi- 
ent gels, Pharmacia). Immunoblotting of the gels with 
anti-c-mvc antibody was as in [22]. 
2.4. [tyrl°-mSl] VIP and casein-resorufin hydrolysis as- 
says 
[tyr w- 125I]VIP prepared as in [28] was incubated with L 
chains at 37°C in 200 ~1 50 mM Tris-HC1, 100 mM 
glycine, 0.025% Tween-20, pH 7.7 for 6 h and peptide 
hydrolysis was estimated by measuring the radioactivity 
soluble in 10% trichloroacetic acid. The estimates of pep- 
tide breakdown from this method are essentially identical 
to those from reversed-phase HPLC separation of intact 
and degraded fragments [3]. Initial rate data at varying 
substrate concentration were fitted to the Michaelis- 
Menten-Henri equation by non-linear egression analysis 
{C' = (Vma×[S] ) / (K  m + [S])} (Enzfitter, Elsevier-Biosoft). 
The kinetic constants were also computed by a graphing 
routine [29], in which the concentrations of the catalyst- 
substrate complex [(CS)] at increasing substrate concentra- 
tions ([St]) were calculated at a series of assumed Ka 
values from the equation: [CS]<[CS]([C t]+ [S t] + K d) + 
[C~][St] = 0. The assumed Kd value giving the best fit (by 
linear regression) between observed reaction velocity and 
[CS] represents the experimentally observed K d for cata- 
lyst-substrate binding. The kca t value was computed as the 
slope of the velocity versus [CS] plot. Cleavage of casein 
labeled with resorufin (200 Ixg/assay tube) was assayed 
according to the manufacturer's instructions (Boehringer- 
Mannheim) under experimental conditions identical to 
those used to measure the hydrolysis of VIP. 
Trichloroacetic acid (final concentration 5%) was added to 
the reaction mixture and the precipitate was removed by 
centrifugation (12 000 × g, 5 min). The presence of re- 
sorufin-labeled casein breakdown products was estimated 
spectrophotometrically (574 nm; Ultrospec III, Pharmacia 
LKB). Bovine pancreatic trypsin (3080 U/mg) was from 
U.S. Biological Corporation, Cleveland, OH. 
2.5. Immunoadsorption 
L chains (200 txl; hkl3, 2 nM; hkl4, 0.5 nM) were 
treated with rabbit anti-human K-chain antibody or control 
anti-human IgG (F c specific) antibody immobilized on 
Sepharose 4B (0.2 ml settled gel) in 50 mM Tris-HC1, 100 
mM glycine, 0.15 M sodium chloride, 0.025% Tween-20 
[3]. Following incubation for 18 h at 4°C, the reaction 
tubes were centrifuged and unadsorbed material in the 
supernatant (50 ILl aliquots) was assayed for [tyr 1°- 125I]VIP 
hydrolysis activity. 
2.6. Nucleotide sequencing 
Nucleotide sequencing of the cDNA inserts in 
pCANTAB5his 6 was by the dideoxynucleotide chain ter- 
mination method [30] using an Applied Biosystems DNA 
Sequenator (Model 373A) and primers LMB3 and fd-SEQ1 
[22]. Sequence analysis was done using the GCG software 
package [31]. The germline V L gene sequence database (V 
BASE, 1994) was provided by I.M. Tomlinson. The num- 
ber of theoretically expected replacement mutations was 
determined [32,33] by comparison of nucleotides 1-285 of 
hkl3 and hkl4 L chains with their putative germline gene 
counterparts u ing software provided by B. Chang and P. 
Casali and a replacement frequency value of 0.8 as defined 
in [33]. When two nucleotide changes occurred in one 
codon, they were counted as separate vents. Sequence 
differences in CDR3 contributed by the J region or in the 
framework I region encoded by the PCR back primer were 
ignored in this analysis. 
3. Results 
3.1. VIP hydrolysis by L chains 
Two human L chains (designated hkl3 and hkl4 L 
chains) previously shown to display VIP binding activity 
[24] were studied for the ability to hydrolyze the peptide. 
In a preliminary experiment, the two human L chains and 
two control murine L chains in bacterial periplasmic ex- 
tracts were fractionated by IMAC on Ni-NTA gel, a 
procedure that yields the recombinant proteins at purities 
> 95%, assessed by SDS-polyacrylamide gelelectrophore- 
sis [23,27]. The proportion of available [tyr l°- 125I]VIP (0.3 
nM; 167,500 cpm) hydrolyzed by the human L chain 
clones hkl3 (1 nM), hkl4 (0.2 nM) and the murine 
catalytic light chain (6 nM; positive control) were 36%, 
kDa 
94  - 
67  - 
43  - 
30  - 
20  - 
14 .4  - 
28 
1 2 
Fig. 1. SDS-polyacrylamide g l electrophoresis (8-25%) of recombinant 
human L chain (clone hkl3). Lane 1, silver-stained L chain; Lane 2, L 
chain immunoblotted with anti-human K-chain antibody. 
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Fig. 2, Saturable VIP hydrolysis by recombinant L chain clone hkl3 (0.37 
nM) and hkl4 (0.06 nM). VIP concentrations, 3-1000 nM mixed with a 
fixed concentration f [tyrULI251]VIP (0.3 nM). Reaction time, 6 h. 
Values are means of closely agreeing duplicates. 
63% and 21%. There was no detectable [tyr]°-]25I]VIP 
hydrolysis by the non-catalytic L chain preparation or the 
eluate from the periplasmic extract of bacteria in which the 
control vector without an L chain insert had been grown. 
Further characterization was performed using hkl3 and 
hk l4  L chains purified on a larger scale from the super- 
natants of bacterial cultures by IMAC on the Ni-NTA gel 
followed by chromatography on a protein L-Sepharose 
column. Electrophoretically homogeneous 28 kDa L chains 
stainable with anti-human L chain antibody (Fig. 1) and 
with anti-c-myc antibody 9El0  (not shown) were obtained 
by this procedure. 
The hydrolysis of VIP by both L chains displayed 
saturation kinetics with increasing VIP concentrations (Fig. 
2). The apparent K m values were in the nanomolar ange 
(Table 1). These K m values are 3-orders of magnitude 
lower than the K m for trypsin-catalyzed VIP hydrolysis 
assayed under similar conditions. Since the catalyst con- 
centration in some assays was in the range of the low end 
of VIP substrate concentrations, kinetic constants were 
also computed by a graphing routine, which eliminates 
errors due to substrate depletion effects (see Section 2). 
Table 1 
Kinetic constants for L chain catalyzed VIP hydrolysis 
Catalyst K m (M) k~,, (min i) k~,t/Kin 
(min ]M -I ] 
hkl3Lchain 1.11Xl0 7(l.10x10 7) 0.22(0.22) 2.0X10 ~ 
hkl4Lchain 2.02×10 7(2.10x10-7) 2.21(2.11) l . lxl07 
Trypsin 3.80X10 4 1.10XI0; 2.9X106 
Cleavage of increasing concentrations of VIP (3-1000 nM) mixed with a 
constant amount of [tyrt°-125I]VIP (0.3 nM) by hkl3 L chain (0.37 nM) 
and hkl4 L chain (0.06 nM) was estimated after incubation at 37°C lot 6 
h. Kinetic constants were derived from initial rates fitted to the 
Michaelis-Menten quation (see Fig. 2). Standard error values were 
< 16c~ of the rneans. Values in parentheses were computed by a graphing 
routine by fitting the rate data to the general equation predicting the 
concentrations of the catalyst-substrate at increasing concentrations of the 
substrate (see Section 2). Data for trypsin are from Ref. [40]. 
The values of k~.at and K 0 (reported as K m in Table 1) 
estimated by this method were essentially identical to the 
kinetic constants computed from the Michaelis-Menten 
equation. Since the K m values approximate the K d val- 
ues, the observed reaction characteristics indicate compara- 
tively high affinity binding of VIP by the L chains. The 
turnover number (kt~at) of hk l4 L chain is about 200-fold 
greater than of a catalytic L chain elicited by immunization 
with VIP [25], and the kinetic efficiency (k~, t /K  m) of this 
L chain (hkl4) for VIP is 3.8-fold superior than of trypsin. 
Turnover of the L chains, however, is slower than that of 
trypsin by 3 -4  orders of magnitude. 
Hydrolysis of casein-resorufin by hkl3 L chain (0.8 
IxM) and hkl4 L chain (0.2 t.tM) was undetectable by a 
spectrophotometric assay. In comparison, 0.2 ~M trypsin 
displayed clearly detectable hydrolysis of this substrate 
(A574 1.1), and the minimal concentration of trypsin at 
which detectable hydrolysis was observed (A574 0.08) was 
0.2 riM. 
Immunoadsorption of hkl3 and hkl4 L chains with 
immobil ized anti-K-chain antibody resulted in near-com- 
plete removal of the VIP hydrolyzing activity. The un- 
bound material in the supernatants recovered after incuba- 
tion of hkl3 and hk l4  L chains with immobil ized anti-K- 
chain antibody hydrolyzed 2.1 4- 1.9% and 4.5 4- 1.5% of 
the available [tyr]°-~25I]VIP, respectively. In comparison, 
supernatants from hkl3 and hkl4 L chains incubated with 
the control immobil ized antibody hydrolyzed 37.0 _+ 3.4% 
and 44.3 + 0.5% of the radiolabeled VIP, respectively. 
Size exclusion chromatography of hkl4 L chain revealed 
20- 
o 15 - r -  
X 








24 28 32 36 40 44 
Retention time, rain 
Fig. 3. Gel filtration of recombinant L chain purified by immobilized 
metal ion and protein L affinity chromatography (clone hkl4, 1.5 t-~g 
protein). Arrows show the elution positions of marker proteins (ovalbu- 
rain, 43 kDa; chymotrypsinogen, 25 kDa; ribonuclease, 13.7 kDa). 
Aliquots of the column fractions (50 I~1) were assayed in duplicate for 
[tyr nL L2~I]VIP (0.14 nM; 84 300 cpm) hydrolyzing activity. 
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elution of the VIP hydrolyzing activity at a molecular mass 
corresponding to the monomer of the protein (Fig. 3). It 
was necessary to keep the concentration of the L chain 
loaded on the column to low levels (300 nM in Fig. 3) to 
recover the activity as shown. At a higher concentrations 
of the L chain (3 IxM), the VIP hydrolyzing activity peak 
and the A:80-protein peak eluted in protein aggregates at 
the column void volume. The tendency of the L chain to 
form aggregates is consistent with previous observations of 
concentration-dependent aggregation of L chains isolated 
from multiple myeloma patients [34,35]. 
(A) 
hk l3  ASP  ILE  VAL  MET THR GLN SER PRO SER SER LED SER ALA SER VAL  
hk l3  gac a tc  g tg  a tg  acc  cag  tct  cca  tcc tcc  c tg  tc t  gca  tc t  g ta  
08 /018 . . . . . .  ca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
08 /018 . . . . . .  GLN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
CDRI  
hk l3  GLY  ASP  ARG VAL  THR ILE SER CYS GLN ALA ARG GLN ASP  ILE ARG 
hk l3  gga  gac  aga gt t  acc a tc  tct  tgc cag  gcg  cgt  caa  gac a t t  aga 
08/018 . . . . . . . . . . .  c . . . . . .  a . . . . . . . . . . .  a . . . .  g . . . . . . . .  c 
08 /018 . . . . . . . . . . . . . . . . .  THR SER . . . . . . . . .  SER 
hk l3  H IS  PHE LEU ASN TRP TYR GLN VAL  LYS  PRO GLY  LYS  ALA PRO LYS  
hk l3  2ac t t t  t ta  aat  tgg  tat  cag  gtg aaa cca  ggg aaa  gcc  cc t  aag 
08/018  a , .  .a  . . . . . . . . . . . . . . . .  ca  . . . . . . . . . . . . . . . . . . . . . .  
08 /018  ASN TYR . . . . . . . . . . . . . . .  GLN . . . . . . . . . . . . . . . . . . . . .  
CDR2 
hk13 LEU LEU ILE  PHE ASP  VAL  THR ANN LEU GLU THR GLY  VAL  PRO ALA 
hk l3  c tg  c tg  a tc  t tc  gat  g tc  acc aat  t tg  gaa aca  ggg gtc  ccg  gca  
08/018 ..c . . . . . . .  a . . . . .  ca  t . . . . . . . . . . . . . . . . . . . . . .  a t.. 
08 /018 . . . . . . . . .  TYR - - -  ALA SER . . . . . . . . . . . . . . . . . . . . .  SER 
hk l3  ARG PHE SER GLY  SER GLY  SER GLY  THR ASP  PHE THR PHE THR ILE 
hk l3  agg  t tc  agt  gga  agt  gga tct  ggg  aca  gat  t tc  ac t  t tc  acc  arc  
08 /018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  t . . . . . . . . . . . .  





hk l3  
hk l3  
08 /018 
08/018 
hk l3  
hk l3  
08 /018 __ .  
08 /018 
SER ARG LEU GLN PRO GLU ASP  ILE ALA THR TYR TYR CYS GLN GLN 
agc  aga  c ta  caa  cc t  gaa  gac  a t t  gca  aca  ta t  tac  tgt  caa  cag  
. . . . .  c . .g  . .g  . . . . . . . .  t . . . . . . . . . . . . . . . . . . . . . . . .  
- - -  SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
CDR3 
SER LYS  SER VAL  PRO TYR THR PHE GLY  GLN GLY  THR LYS  LEU GLU 
to t  aaa  agt  g tc  ccg  tac act  t t t  ggc cag  ggg acc aag  c ta  gag  
.a .g . t  .a. c . . . .  t 
TYR ASP  ASN LEU ---  
ILE GLU 
arc  gaa 
(B) 
hk l4  ARG ILE V~L MET THR GLN SER PRO SER SER LEU SER ALA SER VAL  
hk l4  cgc  atc  g tg  a tg  acc  cag  tc t  cca  tcc tcc  c tg  tc t  gca  tc t  g ta  
I]2/012 . . . . . .  ca  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
02 /012 . . . . . .  GLN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
CDRI  
hk l4  GLY  ASP  ARG VAL  THR ILE THR CYS ARG ALA SER LEU LYS  ILE ILE 
hk l4  gga  gac  aga  gtc  acc  atc  act  tgc cgg  gca  agt  c t t  aag  att  arc  
02 /012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ag .gc . . . .  g. 
02 /012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  GLN SER - - -  SER 




hk l4  
hk l4  
02 /012 
02/012 
ASN PHE LEU SER TRP TYR GLN GLN LYS  PRO GLY  LYS  ALA PRO LYS  
aac t i t  t ta  agt  tgg  ta t  cag  cag  aaa  cca  ggg aaa gcc cc t  aaa 
.g. .a . . . . .  a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  g 
SER TYR - - -  ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
CDR2 
LEU VAL  LEU TYR ALA ALA SER THR L£U GLN SER GLY  VAL  PRO SER 
CtC  gtc  c tc  tat  gca  gca  tct  ac t  t tg  caa  agt  ggg  gtc  cca  tca  
... c .g  a . . . . . . .  t . . . . .  c .g . . . . . . . . . . . . . . . . . . . . . .  
- - -  LEU ILE . . . . . . . . . . . .  SER . . . . . . . . . . . . . . . . . . . . .  
hk14 ARG PHE SER GLY  SER GLY  SER GLY  THR ASP  PHE THR LEU THR ILE  
hk l4  agg  t tc  agt  ggc  agt  gga tct  ggg  aca gat  t t t  ac t  c tc  acc arc  
02 /012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  c . . . . . . . . . . . .  
02 /012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
hk l4  SER SER LEU GLN PRO GLU ASP  LEU ALA THR TYR TYR CYS GLN GLN 
hk l4  agc  agt  c tg  caa  cct  gaa gat  t ta  gca  act  ta t  tac tg t  caa  cag  
02/012 . . . . . . . . . . . . . . . . . . . . . . .  t . . . . . . . .  c . . . . . . . . . . . .  
02 /012 . . . . . . . . . . . . . . . . . . . . .  PHE . . . . . . . . . . . . . . . . . . . . .  
CDR3 
hk14 SER TYR ILE LEU PRO PRO THR PHE GLY  GLY  GLY  THR LYS  VAL  ASP  
hk l4  agt  tac att  ctc  ccg  ccc  act  t tc  ggg  gga  ggg acc aag  gtg  gac 
02 /012 . . . . . . .  g. ac. ..t 
02 /012 SER THR - - -  
hk l4  ILE LEU 
hk l4  a=c t ta  
02 /012 
02/012 
Fig. 4. Nucleotide and deduced amino acid sequences of the variable 
regions of L chain clones hkl 3 (A; GenBank accession number L43498) 
and hkl4 (B: GenBank accession number L43499). The germline gene 
sequences ch)sest in sequence to hkl3 and hkl4 L chains are also shown. 
CDRs are underlined. Dots and dashes represent conserved nucleotides 
and amino acids, respectively. J regions are shown as a solid line. 
3.2. Sequence of L chains 
Comparison of their nucleotide sequence with the Kabat 
database [36] suggested that both L chains belong to the K I 
subgroup (Fig. 4). The two L chains use different J 
segments; JK 2 (hk 13) and JK4 (hk 14). According to Zachau 
and coworkers [37,38], the criterion for correct germline 
gene assignment of mature K-chains is observation of 38 or 
less nucleotide nonidentities with a known germline gene. 
The germline V L genes with greatest sequence identity to 
hkl3 and hkl4 L chains are O8/O18 (28 nucleotide 
nonidentities) and O2/O12 (23 nonidentities), respec- 
tively. Assuming that these are the germline genes of 
origin, both catalytic L chains appear to be extensively 
mutated, with the replacement mutations clustered in the 
CDRs. The number of replacement mutations in the CDRs 
is greater than in the framework regions (hkl3, 11 and 6, 
respectively; hkl4, 12 and 3, respectively). The replace- 
ment to silent mutation ratios in the CDRs and framework 
regions are: hkl3, 11:3 and 6:7, respectively; hkl4, 12:3 
and 3:4, respectively. The probabilities of clustering of the 
replacement mutations in the L chain CDRs by a random 
process are: hkl4, P = 0.01; and hkl3. P = 0.07. 
4. Discussion 
The observation of sequence identities between some 
immunoglobulin L chains and the active site regions of 
serine proteases lead Erhan and Greller [39] to propose that 
L chains may possess proteolytic activity. This has been 
substantiated by observations that a polyclonal autoanti- 
body L chain preparation [20] and the L chain of a murine 
antibody raised to VIP catalyze the cleavage of this 
polypeptide [25,40]. Contrary to the expectation that anti- 
body catalysis is a rare phenomenon, recent observations 
suggest that the majority of monoclonal L chains isolated 
from multiple myeloma patients are capable of cleaving 
synthetic peptide substrates [41]. These considerations 
prompted us to apply phage display techniques to isolate 
VIP-hydrolyzing autoantibody L chains from an asthma 
patient. Two L chains expressed on phage particles and 
isolated by binding to immobilized VIP were purified to 
electrophoretic homogeneity. Both L chains hydrolyzed 
VIP. Evidence that the L chains are responsible for the 
observed catalytic activity consists of observations that a 
control non-catalytic murine L chain purified in parallel 
with the human L chains showed no activity, the mass of 
the hydrolytic activity corresponded to the monomer form 
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of the L chain (27 kDa), the activity was lost by im- 
munoadsorption with specific anti-human K-chain anti- 
body, and the hydrolytic activity was characterized by high 
affinity VIP recognition. 
One significant advance reported in this paper is the 
observation of kinetically efficient hydrolysis of VIP by 
the recombinant human L chains. The turnover of these L 
chains is in the same range as of polyclonal autoantibodies 
described to hydrolyze VIP [2,3] and substantially greater 
than of monoclonal L chains elicited by immunization with 
VIP [25]. Although the apparent turnover of the L chains is 
low compared to trypsin, their K m for VIP is approxi- 
mately three-orders of magnitude lower than of trypsin, a 
highly evolved catalyst. Thus, the catalytic efficiency of 
the L chains is comparable to that of trypsin. Trypsin 
hydrolyzes polypeptide substrates relatively indiscrimi- 
nately. In contrast, neither L chain hydrolyzed casein, 
suggesting that these catalysts are specialized to recognize 
VIP. The K m and Ka values of the L chain were compa- 
rable, confirming high affinity recognition of VIP by these 
catalysts. This is a distinguishing characteristic of natural 
antibody catalysis, arising from recognition of antigenic 
epitopes composed of multiple amino acids [42]. In com- 
parison, conventional enzymes like trypsin display high 
g m values and substrate recognition occurs primarily at 
amino acids at or immediately flanking the scissile bond. 
The second significant observation is that the two L 
chains are extensively mutated compared to their putative 
germline gene counterparts. The replacement mutations 
tend to cluster in the CDRs, suggesting that the L chains 
are products of an antigen-driven affinity maturation pro- 
cess. The identity of antigens responsible for formation of 
autoantibodies with VIP binding and hydrolyzing activities 
in asthma is not known. As noted previously [19], the 
inciting immunogen could be endogenous VIP itself or a 
structurally related peptide of microbial or dietary origin. 
Regardless of the uncertainty about the antigenic stimulus, 
the development of catalytic activity in L chains appears to 
be compatible with the process of affinity maturation. This 
conclusion is supported by: (a) the presence of replace- 
ment mutations in the CDRs of the L chains described in 
the present study, their ability to recognize VIP with 
sub-micromolar K m and their efficient peptide-bond hy- 
drolyzing activities, and (b) frequent expression of prote- 
olytic activity by L chains secreted by B-lymphocyte 
tumors in multiple myeloma patients [41]. Since the tumors 
in multiple myeloma patients arise at an advanced stage of 
B-lymphocyte differentiation [43], the catalytic activity can 
be assumed to survive the process of antigen-driven clonal 
selection. 
Further analysis by site-directed mutagenesis and other 
techniques will be necessary to identify the three-dimen- 
sional structural composition of the catalytic sites in the L 
chains and the structural factors underlying their distinct 
properties. Seventeen of the twenty-seven amino acids 
constituting the CDRs of hkl3 and hkl4 L chains are 
non-identical. The putative germline genes from which the 
two L chains are derived are different (O8/O18 and 
O2/O12). Both L chains display sequence differences in 
their CDRs compared to a murine anti-VIP L chain with 
well characterized catalytic activity [25,27]. In particular, 
two residues identified by site-directed mutagenesis to be 
essential for catalysis by the murine L chain (Ser27a and 
His93) [27] are replaced in the human L chains by amino 
acids with dissimilar chemical reactivities. A Ser and an 
Ile residues are found at position 93 in hkl3 and hkl4 L 
chains, respectively. Neither L chain contains a position 
27a residue (see Kabat et al. [36] for numbering system; 
position 28 in hkl3 and hkl4 L chains is occupied by Asp 
and Lys residues, respectively). Catalysis by the various L 
chains does not appear to be mediated, therefore, by a 
common catalytic site. 
The availability of recombinant catalytic L chains with 
VIP-specific hydrolytic activity can be anticipated to facili- 
tate the study of the functional role and utility of the 
catalytic antibodies. Observations of substrate-specific and 
kinetically efficient catalysis by autoantibodies present in 
autoimmune disease have raised the possibility that cat- 
alytic antibodies may mediate the pathological depletion of 
individual polypeptide substrates. Depletion of VIP has 
been observed in the airways obtained at autopsy from 
patients with fatal asthma [44], although analysis of tissues 
from patients with less severe asthma does not reveal 
decreased VIP levels [45]. Autoantibodies to VIP are also 
found in lupus. In view of the potent anti-inflammatory 
effects of VIP [16,46,47], it can be hypothesized that the 
autoantibodies contribute in the generalized increase in 
inflammatory reactions een in lupus. The L chains de- 
scribed in the present study offer a means to achieve 
depletion of VIP and study the functional consequences of 
this event, for example, in passively immunized experi- 
mental animals. The anti-VIP L chains also offer the first 
opportunity to examine the therapeutic utility of catalytic 
antibodies. Various tumor cells are known to synthesize 
VIP and utilize this peptide as a growth factor via an 
autocrine mechanism [17,18]. Study of the growth in- 
hibitory effect of catalytic antibodies to VIP in these types 
of tumors is warranted. 
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